Patents by Inventor Bryan D. Fleming

Bryan D. Fleming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES
    Publication number: 20240401239
    Abstract: Methods for producing synthetic single-domain monoclonal antibody libraries using humanized llama nanobody framework sequences, libraries obtainable by the method, as well as antibodies selected from the libraries are described. In particular, synthetic single-domain monoclonal antibodies that specifically bind to the spike protein of SARS-COV-2 and neutralize SARS-COV-2 infection are described. Use of the disclosed antibodies for the detection, prophylaxis and treatment of SARS-COV-2 infection is described.
    Type: Application
    Filed: September 9, 2022
    Publication date: December 5, 2024
    Applicant: The U.S.A., as represented by The Secretary, Department of Health and Human Services
    Inventors: Ying Fu, Bryan D. Fleming, Alex Renn, Matthew D. Hall, Anton Simeonov
  • HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF
    Publication number: 20240301084
    Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Nan Li, Bryan D. Fleming
  • High affinity monoclonal antibodies targeting glypican-2 and uses thereof
    Patent number: 12012463
    Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: June 18, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Nan Li, Bryan D. Fleming
  • HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF
    Publication number: 20210292428
    Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.
    Type: Application
    Filed: August 6, 2019
    Publication date: September 23, 2021
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Mitchell Ho, Nan Li, Bryan D. Fleming